by | Nov 19, 2021 | Uncategorized
Source: Healio News The FDA granted orphan drug designation to GC012F, a novel chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory multiple myeloma.GC012F (Gracell Biotechnologies) is an autologous, gene-edited, bispecific CAR-T that...
by | Nov 19, 2021 | Uncategorized
Source: Cure Today articles An expert explains how two common myeloma treatments – CAR-T cell therapy and bi-specific antibodies – work, and which patients may want to steer clear from these treatment modalities. Read More
by | Nov 12, 2021 | Uncategorized
Source: Healio News Chimeric antigen receptor T-cell therapy has induced exceptional response rates among patients with relapsed or refractory multiple myeloma compared with conventional options, according to a speaker at Chemotherapy Foundation Symposium.Shambavi...
by | Nov 8, 2021 | Uncategorized
Source: Healio News The FDA granted fast track designation to EZM0414 for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.EZM0414 (Epizyme) is an oral SETD2 inhibitor. SETD2 is a histone methyltransferase that plays several important...
by | Nov 4, 2021 | Uncategorized
Source: Healio News Novel therapies and treatment strategies could help to address the clinical challenges of triple-class refractory multiple myeloma, according to a speaker at Chemotherapy Foundation Symposium.“Triple-class refractory multiple myeloma is kind of the...
by | Nov 2, 2021 | Uncategorized
Source: Healio News The FDA has delayed its decision on a biologics license application for ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory multiple myeloma.Ciltacabtagene autoleucel (Janssen,...
